News

  • 26 September 2011

    Acetylon begins Phase I/IIa trial of ACY-1215 drug

    Acetylon Pharmaceuticals has initiated a Phase I/IIa clinical trial of ACY-1215, an oral Class II histone deacetylase inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

  • 22 September 2011

    Merck opens Irish R&D facility

    US-based pharmaceutical major Merck has opened a €100m R&D facility at Ballydine, Co Tipperary, Ireland.

  • 21 September 2011

    Sanofi to enter lucrative acne market

    France-based pharmaceutical major Sanofi has acquired the rights to an investigational acne treatment, signalling a move into the lucrative market.

Close
Close
Close

Go Top